

Journal Pre-proof

Risk Factors for SARS-CoV2 Infection in Pregnant Women

Ms. Allie SAKOWICZ, MS, Mr. Alexander E. AYALA, BA, Ms. Chideraa C. UKEJE, BA, Ms. Celeste S. WITTING, BS, William A. GROBMAN, MD, MBA, Emily S. MILLER, MD, MPH



PII: S2589-9333(20)30154-3

DOI: <https://doi.org/10.1016/j.ajogmf.2020.100198>

Reference: AJOGMF 100198

To appear in: *American Journal of Obstetrics & Gynecology MFM*

Received Date: 25 June 2020

Revised Date: 22 July 2020

Accepted Date: 25 July 2020

Please cite this article as: SAKOWICZ A, AYALA AE, UKEJE CC, WITTING CS, GROBMAN WA, MILLER ES, Risk Factors for SARS-CoV2 Infection in Pregnant Women, *American Journal of Obstetrics & Gynecology MFM* (2020), doi: <https://doi.org/10.1016/j.ajogmf.2020.100198>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Inc.

Risk Factors for SARS-CoV2 Infection in Pregnant Women

Ms. Allie SAKOWICZ, MS¹, Mr. Alexander E. AYALA, BA², Ms. Chideraa C. UKEJE, BA², Ms. Celeste S. WITTING, BS², William A. GROBMAN, MD, MBA¹, Emily S. MILLER, MD, MPH¹

1. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, 60611, USA.
2. Northwestern University Feinberg School of Medicine, Chicago, Illinois, 60611, USA.

Disclosures: The authors report no conflict of interest.

Funding: Research reported in this publication was supported, in part, by the National Institutes of Health's National Center for Advancing Translational Sciences, Grant Number UL1TR001422. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Corresponding Author: Allie Sakowicz, MS, 250 E. Superior St., Room 05-2175, Chicago, IL 60611; Phone: 847-602-7713; Fax: 312-472-3740; e-mail:

Allison.Sakowicz@northwestern.edu

Word count (abstract): 351

Word count (main text): 2940

Journal Pre-proof

1 **Condensation:** In addition to previously identified risk factors, having living children at
2 home represents a significant risk factor for infection with SARS-CoV2 among pregnant
3 women.

4
5 **Short Title:** SARS-CoV2 Risk Factors in Pregnancy

6
7 **AJOG at a Glance:**

8 A. Why was the study conducted?

9 Risk factors for SARS-CoV2 infection in pregnancy remain poorly understood.
10 Identifying those populations at heightened risk of acquisition is essential to
11 effectively target outreach and prevention efforts.

12 B. What are the key findings?

13 Compared to women who tested negative for SARS-CoV2, women who tested
14 positive were younger and were more likely to have public insurance, to identify
15 as Black/African-American or Latina, to be unmarried, to be obese, have pre-
16 existing pulmonary disease, and have living children. An increasing number of
17 living children was associated with an increasing risk of SARS-CoV2 infection
18 and this finding persisted after controlling for potential confounders.

19 C. What does this study add to what is already known?

20 In addition to previously identified risk factors, having living children at home
21 represents a significant risk factor for infection with SARS-CoV2 among pregnant
22 women.

23 **Keywords:** COVID-19, health disparities, perinatal epidemiology, social determinants of

24 health

25

Journal Pre-proof

26 Abstract

27 **Background:** Risk factors for SARS-CoV2 infection in pregnancy remain poorly
28 understood. Understanding populations at heightened risk of acquisition is essential to
29 more effectively target outreach and prevention efforts.

30

31 **Objective:** To compare sociodemographic and clinical characteristics of pregnant women
32 with and without SARS-CoV2 infection and, among those with SARS-CoV2, to compare
33 characteristics of those who reported COVID-19 symptoms and those who were
34 asymptomatic at diagnosis.

35

36 **Study Design:** This retrospective cohort study includes pregnant women who delivered
37 or intended to deliver at Northwestern Memorial Hospital after initiation of a universal
38 testing protocol on admission (April 8, 2020 - May 31, 2020). Women were
39 dichotomized by whether they tested positive for SARS-CoV2. Among women who
40 tested positive, women were further dichotomized by whether they endorsed symptoms
41 of COVID-19. Bivariable analysis, and non-parametric tests of trend were used for
42 analyses. Logistic regression was used to control for potential confounders as well as to
43 examine effect modification between race and ethnicity and any other identified risk
44 factors.

45

46 **Results:** During the study period, 1,418 women met inclusion criteria, of whom 101
47 (7.1%) tested positive for SARS-CoV2. Of the 101 women who tested positive, 77
48 (76.2%) were symptomatic at the time of diagnosis. Compared to women who tested

49 negative for SARS-CoV2, women who tested positive were younger and were more
50 likely to have public insurance, to identify as Black/African-American or Latina, to be
51 unmarried, to be obese, have pre-existing pulmonary disease, and have living children.
52 An increasing number of living children was associated with an increasing risk of SARS-
53 CoV2 infection and this finding persisted after controlling for potential confounders.
54 There was no effect modification between race or ethnicity and having living children
55 with regard to the risk of infection. There were no significant differences identified
56 between women who were symptomatic and asymptomatic.

57

58 **Conclusion:** Many risk factors for SARS-CoV2 infection in pregnancy are similar to the
59 social and structural determinants of health that have been reported in the general
60 population. The observed association between SARS-CoV2 infection and having children
61 raises the possibility of children themselves as vectors of viral spread or behavior patterns
62 of parents as mediators of acquisition.

63

64 Introduction

65
66 Since December 2019, Coronavirus Disease 2019 (COVID-19) has spread rapidly
67 throughout the world. It has now caused over fourteen million infections worldwide, with
68 over three million infections in the United States^{1,2}. Emerging antibody surveillance data
69 have suggested that many individuals infected with severe acute respiratory syndrome
70 coronavirus 2 (SARS-CoV2) do not manifest clinical symptoms. As such, many cases of
71 the infection are thought to be as a result of spread from asymptomatic individuals^{3,4}.
72 Infection with SARS-CoV2 in pregnancy has been associated, in some studies, with
73 higher rates of miscarriage, preterm birth, and preeclampsia⁵. The neonates born to
74 women with SARS-CoV2 have been found to have higher rates of perinatal mortality and
75 admission to the neonatal intensive care unit⁵. Accurately identifying pregnant women
76 infected with SARS-CoV2 is imperative for appropriate management and treatment.
77 Their identification also allows frontline healthcare workers to improve their protection
78 and take precautions to mitigate the spread of the virus.

79
80 Little research has been conducted on risk factors for SARS-CoV2 infection specific to
81 pregnant women. Whether observed associations in the general population apply to
82 pregnant women, or whether unique risk factors can be identified specific to pregnant
83 women, is unknown. For example, an overrepresentation of racial and ethnic minority
84 groups in COVID-19 hospitalizations and deaths has been demonstrated in the general
85 population^{6,7}. However, whether these disparities remain true among pregnant women,
86 who may have different behaviors and exposures, has not been investigated. The
87 American College of Obstetrics and Gynecology (ACOG) recently called for health

88 institutions to collect data on SARS-CoV2 testing and outcomes that can recognize and
89 examine the ways in which health care systems perpetuate racial inequalities in access to
90 care and in health outcomes⁸. Robust research on these factors can help institutions
91 determine the most efficient way to distribute scarce resources to those women most in
92 need.

93
94 Public health interventions, such as school closures, have been shown to decrease the risk
95 of community viral spread on a population level⁹. Epidemiologists have found that while
96 children are less likely to exhibit SARS-CoV2 symptoms compared to adults^{10,11}, they
97 also have more subtle presentations¹¹⁻¹³ and may spread disease to family members at
98 home^{14,15}. On an individual level, these data suggest that families with children at home,
99 particularly families who are not able to physically distance, may be at higher risk of
100 SARS-CoV2 acquisition. As many pregnant women in the United States have young
101 children at home, they may be a particularly vulnerable population for SARS-CoV2
102 acquisition, but this association has not been previously evaluated.

103
104 Universal SARS-CoV2 testing among pregnant women represents an opportunity to
105 better understand epidemiologic risk factors. As our hospital is a large volume center
106 located in a high prevalence region of the United States, our objective was to leverage
107 data ascertained from our testing policies to characterize the epidemiology of SARS-
108 CoV2 infection overall, as well as symptomatic infection, among pregnant women.

109
110

111 **Materials and Methods**

112 *Study Design*

113 This retrospective cohort study includes pregnant women who were tested for SARS-
114 CoV2 at Northwestern Memorial Hospital or affiliated outpatient clinics between March
115 19, 2020 and May 31, 2020. Northwestern Memorial Hospital is a tertiary care referral
116 center in which approximately 12,000 deliveries are performed annually. Routine care
117 during the entire study period was to perform systematic screening using a
118 comprehensive list of reported symptoms for COVID-19, including fever, shortness of
119 breath, cough, sore throat, body aches, chills, new onset vomiting, diarrhea, loss of taste
120 or smell, or red or painful eyes.

121
122 Beginning on March 19, 2020, women who presented with clinical concern for COVID-
123 19 underwent testing for SARS-CoV2. Universal point-of-care testing for SARS-CoV2
124 was performed for all women presenting for delivery or with pregnancy complications
125 necessitating admission to the Labor & Delivery or Antepartum unit after April 8, 2020.
126 During the time period of March 19 to April 7, 2020, women who were symptomatic and
127 tested positive for SARS-CoV2 were included. During the time period of April 8 to May
128 19, 2020, all women who were tested for SARS-CoV2, including symptomatic and
129 asymptomatic positive patients as well as patients who tested negative, were included.
130 During the time period of May 20 to May 31, 2020, only women who tested positive for
131 SARS-CoV2, both symptomatic and asymptomatic, were included. Women with
132 scheduled admissions were tested 12-36 hours prior to the admission at a designated
133 drive-through testing center using an in-house polymerase chain reaction (PCR)-based

134 platform with an 8-hour turnaround time. Women who presented in labor or with another
135 unscheduled indication for admission were tested either in obstetric triage or on the Labor
136 & Delivery unit using a commercially available PCR-based platform with a 2-3 hour
137 turnaround time. Women who tested negative at admission but who developed possible
138 symptoms of COVID-19 (e.g., an intrapartum fever without an alternative diagnosis)
139 were retested as clinically indicated.

140

141 Testing was performed on nasopharyngeal specimens that were collected by registered
142 nurses with special training in the proper collection and handling of the specimen.

143

144 *Data Collection*

145 Electronic health records were reviewed for all pregnant women identified to have a
146 SARS-CoV2 test performed. Demographic and clinical data included maternal age, self-
147 reported race/ethnicity, and insurance status. Medical history data included body mass
148 index at delivery, tobacco use, and any identified maternal pre-existing disease (e.g.,
149 diabetes, hypertension, pulmonary disease). Obstetric data included parity (e.g., term
150 births, preterm births, and living children). The systematic symptom assessment was
151 entered into the EHR in a form completed by the admitting nurse and was abstracted to
152 the database. Details of the SARS-CoV2 testing platform utilized, as well as test results,
153 were also abstracted. Data were entered into the research electronic data capture system
154 (REDCap)¹⁶ and missing or aberrant data were re-reviewed by systematic assessment of
155 the database.

156

157 *Statistical Analysis*

158 Women were dichotomized by their SARS-CoV2 test results. For women who tested
159 positive, they were further dichotomized by whether they exhibited any symptoms of
160 COVID-19 on the systematic review. Bivariable analyses were used to compare the
161 clinical characteristics associated with women who did and did not test positive for
162 SARS-CoV2. Mann Whitney U tests were used for continuous variables and chi squared
163 or Fisher's exact tests were used for categorical variables. A non-parametric test of trend
164 was performed to identify whether an increasing number of children was associated with
165 SARS-CoV2 positivity.

166

167 Logistic regression was performed to control for potential confounders in the relationship
168 between having children and SARS-CoV2 infection. Race, ethnicity, public insurance,
169 and marital status ultimately reflect overlapping constructs without direct biological
170 mechanisms for SARS-CoV2 acquisition. Accordingly, only insurance was included in
171 the primary model as it was felt to best reflect social and structural determinants of
172 health. This regression otherwise included variables associated with SARS-CoV2
173 infection in bivariable analysis with $p < 0.05$. A sensitivity analysis was performed
174 including all variables associated with SARS-CoV2 infection ($p < 0.05$). Interaction terms
175 were used to evaluate potential effect modification between race or ethnicity and having
176 living children. Data were analyzed with Stata Version 15 (College Station, TX). This
177 study was approved by the Northwestern University Institutional Review Board with a
178 waiver of consent prior to its initiation.

179

180 Results*181 Patient Characteristics*

182 During the study period, 1,510 SARS-CoV2 tests were performed on 1,418 unique
183 pregnant women at Northwestern Memorial Hospital. Of these 1,418 women, 101 (7.1%)
184 tested positive for SARS-CoV2. No patients declined SARS-CoV2 testing during the
185 study period.

186

187 Women with SARS-CoV2 infection

188 The demographic characteristics of the cohort are presented in Table 1. Compared to
189 women who tested negative, women who tested positive for SARS-CoV2 were younger
190 and more likely to be publicly insured, to identify with a racial or ethnic minority group,
191 and to be unmarried. In addition, women who tested positive for SARS-CoV2 were more
192 likely to be obese and to have a pre-existing pulmonary disease. In terms of obstetric
193 characteristics, women who tested positive for SARS-CoV2 were less likely to be
194 nulliparous and, accordingly, were more likely to have living children. Furthermore, an
195 increasing number of living children was associated with an increased prevalence of
196 SARS-CoV2 infection (Figure 1, $p < 0.001$ for test of trend). Specifically, compared to
197 women without any living children, women with more living children exhibited an
198 increasing odds of testing positive for SARS-CoV2 [OR 2.5 (95% CI 1.5-4.0); OR 2.1
199 (95% CI 1.0-4.1); OR 4.1 (95% CI 1.6-10.5); OR 7.0 (95% CI 2.8-17.7), for having 1, 2,
200 3, or at least 4 living children, respectively).

201

202 In multivariable analyses of the relationship between having living children and SARS-
203 CoV2 infection (including maternal age, insurance, obesity, and pulmonary disease as
204 potential confounders), having living children remained significantly associated with
205 SARS-CoV2 infection (Table 2). Inclusion of all variables in the model that were
206 significantly associated with SARS-CoV2 infection did not substantively change the
207 association (aOR 2.29, 95% CI 1.11-4.74). There was no significant effect modification
208 between race or ethnicity and number of living children with respect to SARS-CoV2
209 infection.

210

211 *Demographics of asymptomatic women with SARS-CoV2 infection*

212 Among women diagnosed with SARS-CoV2, 77 (76.2%) were symptomatic upon
213 presentation (Table 3). Importantly, these data included epochs wherein only women with
214 overt symptoms of COVID-19 could be tested for SARS-CoV2. Accordingly, 76.2% is
215 not reflective of population level symptom prevalence. No significant differences
216 between women who presented with and without symptoms were found in terms of
217 maternal age, use of public insurance, nulliparity, number of living children, race,
218 ethnicity, marriage status, BMI at delivery, rates of obesity, tobacco use, presence of any
219 maternal chronic disease, rates of pre-existing diabetes, rates of hypertension, rates of
220 pulmonary disease, and rates of gestational diabetes.

221

222 **Discussion**

223 *Principal Findings*

224 In this large observational cohort of pregnant women tested for SARS-CoV2 in an
225 epidemiologic epicenter within the United States, we identified several risk factors for
226 SARS-CoV2 infection including identifying with a racial or ethnic minority subgroup or
227 having living children. SARS-CoV2 has previously been documented to
228 disproportionately affect racial and ethnic minorities¹⁷, but to the best of our knowledge,
229 this is the first study that identifies these associations in pregnant women. Moreover, this
230 is the first study to identify having living children as a risk factor for SARS-CoV2
231 infection.

232

233 *Results and Clinical Implications*

234 These data demonstrate that women with living children at home were more likely to be
235 infected with SARS-CoV2. Although children make up only 1-2% of all known SARS-
236 CoV2 cases¹⁴, their presentation is often more subtle and may be missed, potentially
237 allowing them to act as vectors of asymptomatic spread. Of children with SARS-CoV2,
238 5-7% are asymptomatic, and 51-65% have only routine upper respiratory symptoms
239 without cough or auscultatory abnormalities^{10,18}. Of children who are symptomatic, the
240 presentation typically includes fever, but they are otherwise less visibly ill and their
241 symptoms are often atypical¹². A recent clinical report describes five children in China
242 who were originally admitted for non-respiratory symptoms, but ultimately tested
243 positive for SARS-CoV2. In this report, four out of the five children studied had GI
244 symptoms as the first manifestation of disease, raising the possibility SARS-CoV2 may
245 not be identified in children at symptom onset¹³. Ultimately, the average number of
246 secondary infections transmitted within a family when a child is diagnosed with SARS-

247 CoV2 is 2.4¹². These data become increasingly important in the context of discussions on
248 school and daycare re-opening across the United States. A recent study from South Korea
249 demonstrated that young children with COVID-19 (under age 10) were roughly half as
250 likely to spread the infection to others, but older children (ages 10 to 19) were more
251 likely to infect other household contacts compared to adults¹⁵. We do not have the age of
252 living children available in our data, and so we are unable to assess whether the age of
253 living children moderates the observed risk. In addition, we are unable to assess whether
254 it is the number of children within the household itself that is a risk factor for SARS-
255 CoV2 acquisition, or whether the number of children at home is a surrogate marker for
256 other structural determinants of health such as decreased capacity to physically distance
257 within the home or increased exposures outside of the home to support the needs of the
258 family. These findings suggest that having children at home may partially explain the
259 increased rate of infection amongst women with living children. While causal attribution
260 cannot be made, the finding of an increasing prevalence of SARS-CoV2 infection with
261 increasing numbers of living children suggests that children may contribute to viral
262 spread among pregnant women.

263

264 Other data has shown that the COVID-19 pandemic is disproportionately affecting
265 individuals who identify as a racial or ethnic minority¹⁹. This relationship has been
266 demonstrated in other pandemics, including the 1918 and 2009 influenza pandemics^{20,21}.
267 Individuals who identify as a minority race or ethnicity may have less of an opportunity
268 to engage in public health prevention strategies due to social and structural determinants
269 of health. One example of this pertains to differences in occupations. According to CDC

270 data, racial/ethnic minority populations in the United States workforce are
271 overrepresented in essential industries. Nearly a quarter of employed Latino/a and Black
272 or African-American workers are employed in service industry jobs as compared to 16%
273 of non-Hispanic white workers²². These workers may not be as readily able to practice
274 risk-reducing social distancing behavior or work from home, increasing their likelihood
275 of exposure to SARS-CoV2. Additionally, they may work within industries that are less
276 likely to have benefits such as paid sick leave²², a measure proven to mitigate contagion
277 of viral respiratory illnesses^{23,24}. Alternatively, the number of living children may reflect
278 a higher household density, independent of children themselves as a vector. This may
279 inhibit ability of pregnant women to social distance and isolate children infected with
280 SARS-CoV2. Finally, residential segregation by race or ethnicity may also contribute to
281 disparities in SARS-CoV2 prevalence.

282

283 These data also reinforce prior findings that SARS-CoV2 infection cannot be reliably
284 identified based on symptomatic screening alone^{25,26}. Universal testing for pregnant
285 women being admitted for labor should be considered in areas of high disease burden as
286 symptomatic screening alone is insufficient to identify all women with SARS-CoV2
287 infection.

288

289 *Strengths & Limitations*

290 An important strength of this study is the large sample size with a relatively high
291 prevalence of SARS-CoV2 infection in our geographic region. However, this study is
292 also subject to limitations. First, these data are limited to a single tertiary care center, and

293 may not be generalizable to other populations. Our data may differ from other institutions
294 given the differences in patient populations between institutions. Future work in other
295 settings may uncover other risk factors not observed in our cohort. Larger multi-center
296 studies focused on pregnant women are an important next step in epidemiologic analyses.
297 Secondly, SARS-CoV2 PCR assays have a wide range of measured false negative rates.
298 A case report has been published that describes a negative nasopharyngeal SARS-CoV2
299 reverse transcriptase (RT) PCR test followed by positive SARS-CoV2 RT PCR using a
300 bronchoalveolar lavage specimen in a pregnant woman²⁷. False negative rates of 17-63%
301 have been reported when using this test in the non-pregnant population^{28,29}. While false
302 negative results would potentially reduce the order of magnitude of identified risk factors,
303 they should not systematically bias our results. Next, this study uses the living children
304 component of parity as a proxy for living children in the home and thus does not account
305 for all social contexts, for example women with children in foster care or children of
306 other family members residing in the home. However, as these contexts are unlikely to
307 systematically bias the associations observed and are epidemiologically uncommon, we
308 do not think the use of this proxy substantially altered the true association. Finally, as
309 symptoms were recorded in a designated form at the time of admission, the possibility
310 remains that there are lapses in this recording system, and thus, women who are classified
311 as asymptomatic did have atypical or mild symptoms or developed symptoms after their
312 admission. Given the novel nature of the COVID-19 pandemic, not all information
313 regarding the virus, disease presentation, or disease progression are known and
314 misclassification remains possible. This study spans a timeframe of April and May 2020,
315 a period of rapid dissemination of infection across Chicago⁷ and a time when school

316 closures were common. Thus, these data may not necessarily be transposable to earlier or
317 later epochs of the pandemic or in areas where other public health strategies were
318 implemented.

319

320 *Research Implications*

321 The identified association between having living children and SARS-CoV2 infection
322 augments growing concern that asymptomatic or mildly symptomatic children may
323 contribute to disease spread. As pregnant women are a population with a disproportionate
324 exposure to young children at home, future research should corroborate this association
325 and evaluate interventions targeted for multiparous women, such as augmented public
326 health messaging about hand-washing and the utilization of masks to prevent airborne
327 transmission.

328 *Conclusions*

329 This study reinforces the significant racial and ethnic disparities that exist in SARS-CoV2
330 infections among pregnant women and the critical need for public health interventions to
331 combat them. Currently, Chicago's Racial Equity Rapid Response Team (RERRT)
332 strives to address COVID-19 related disparities with targeted interventions³⁰. RERRT
333 aims to increase testing in Southside Chicago, host virtual town halls in underserved
334 neighborhoods, and overall lessen the burden that this unprecedented public health crisis
335 has created for Chicago's racial and ethnic minority groups. Similar community efforts
336 focused on health equity will be important to attempt to mitigate the observed disparities.

337 In addition to recognizing the racial and ethnic disparities in identified SARS-CoV2

338 infections, obstetric clinicians must consider how changes in obstetric care delivery for
339 women diagnosed with SARS-CoV2 may disproportionately affect socially vulnerable or
340 disadvantaged women³¹. Awareness of the epidemiologic factors associated with SARS-
341 CoV2 infection in pregnancy and the corresponding disparities that exist is the requisite
342 first step to improving health equity. The onus is on us to ensure it is not the only step.

343

Journal Pre-proof

344 **References**

- 345 1. World Health Organization. *COVID-19 Situation Report - 183.*; 2020. Accessed
346 July 22, 2020. [https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)
347 [2019/situation-reports](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)
- 348 2. CDC. Coronavirus Disease 2019 (COVID-19) in the U.S. Centers for Disease
349 Control and Prevention. Published 2020. Accessed July 22, 2020.
350 <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html>
- 351 3. Arons M, Hatfield K, Reddy S, Kimball A. Presymptomatic SARS-CoV-2
352 Infections and Transmission in a Skilled Nursing Facility. *N Engl J Med*. Published
353 online April 24, 2020. Accessed May 14, 2020. [https://www-nejm-](https://www.nejm-org.ezproxy.galter.northwestern.edu/doi/full/10.1056/NEJMoa2008457)
354 [org.ezproxy.galter.northwestern.edu/doi/full/10.1056/NEJMoa2008457](https://www.nejm-org.ezproxy.galter.northwestern.edu/doi/full/10.1056/NEJMoa2008457)
- 355 4. Office of Governor Andrew M. Cuomo. Amid Ongoing COVID-19 Pandemic,
356 Governor Cuomo Announces Results of Completed Antibody Testing Study of
357 15,000 People Showing 12.3 Percent of Population Has COVID-19 Antibodies
358 [Press Release]. Published online May 2, 2020. Accessed May 14, 2020.
359 [https://www.governor.ny.gov/news/amid-ongoing-covid-19-pandemic-governor-](https://www.governor.ny.gov/news/amid-ongoing-covid-19-pandemic-governor-cuomo-announces-results-completed-antibody-testing)
360 [cuomo-announces-results-completed-antibody-testing](https://www.governor.ny.gov/news/amid-ongoing-covid-19-pandemic-governor-cuomo-announces-results-completed-antibody-testing)
- 361 5. Di Mascio D, Khalil A, Saccone G, et al. Outcome of coronavirus spectrum
362 infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and
363 meta-analysis. *Am J Obstet Gynecol MFM*. Published online March 25,
364 2020:100107. doi:10.1016/j.ajogmf.2020.100107

- 365 6. APM Research Lab Staff. *The Color of Coronavirus: COVID-19 Deaths by Race*
366 *and Ethnicity in the U.S.* APM Research Lab; 2020. Accessed May 14, 2020.
367 <https://www.apmresearchlab.org/covid/deaths-by-race>
- 368 7. Illinois Department of Public Health. *COVID-19 Statistics*. IDPH; 2020. Accessed
369 May 14, 2020. <https://www.dph.illinois.gov/covid19/covid19-statistics>
- 370 8. American College of Obstetricians and Gynecologists. Position Statement:
371 Addressing Health Equity During the COVID-19 Pandemic. Published online May
372 11, 2020. Accessed May 14, 2020. <https://www.acog.org/en/Clinical>
373 Information/Policy and Position Statements/Position Statements/2020/Addressing
374 Health Equity During the COVID-19 Pandemic
- 375 9. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS.
376 Strategies for mitigating an influenza pandemic. *Nature*. 2006;442(7101):448-452.
377 doi:10.1038/nature04795
- 378 10. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 Among Children in China.
379 *Pediatrics*. Published online March 31, 2020. doi:10.1542/peds.2020-0702
- 380 11. Di Nardo M, van Leeuwen G, Loreti A, et al. A literature review of 2019 novel
381 coronavirus (SARS-CoV2) infection in neonates and children. *Pediatr Res*.
382 Published online July 17, 2020:1-12. doi:10.1038/s41390-020-1065-5
- 383 12. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and
384 potential evidence for persistent fecal viral shedding. *Nat Med*. 2020;26(4):502-505.
385 doi:10.1038/s41591-020-0817-4

- 386 13. Cai X, Ma Y, Li S, Chen Y, Rong Z, Li W. Clinical Characteristics of 5 COVID-19
387 Cases With Non-respiratory Symptoms as the First Manifestation in Children. *Front*
388 *Pediatr.* 2020;8. doi:10.3389/fped.2020.00258
- 389 14. She J, Liu L, Liu W. COVID-19 epidemic: Disease characteristics in children. *J*
390 *Med Virol.* Published online March 31, 2020:1-8. doi:10.1002/jmv.25807
- 391 15. Park YJ, Choe YJ, Park O, et al. Contact Tracing during Coronavirus Disease
392 Outbreak, South Korea, 2020 (Early Release). *Emerg Infect Dis.* 2020;26(10).
393 doi:10.3201/eid2610.201315
- 394 16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
395 Electronic Data Capture (REDCap) - A metadata-driven methodology and workflow
396 process for providing translational research informatics support. *J Biomed Inform.*
397 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010
- 398 17. Laurencin CT, McClinton A. The COVID-19 Pandemic: a Call to Action to Identify
399 and Address Racial and Ethnic Disparities. *J Racial Ethn Health Disparities.* Published
400 online April 18, 2020:1-5. doi:10.1007/s40615-020-00756-0
- 401
402 18. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated
403 with the 2019 novel coronavirus indicating person-to-person transmission: a study
404 of a family cluster. *The Lancet.* 2020;395(10223):514-523. doi:10.1016/S0140-
405 6736(20)30154-9
- 406 19. Centers for Disease Control. COVID-19 in Racial and Ethnic Minority Groups. *Cent*
407 *Dis Control Prev.* Published online April 22, 2020. Accessed May 14, 2020.

- 408 <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic->
409 [minorities.html](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic-minorities.html)
- 410 20. Grantz KH, Rane MS, Salje H, Glass GE, Schachterle SE, Cummings DAT.
411 Disparities in influenza mortality and transmission related to sociodemographic
412 factors within Chicago in the pandemic of 1918. *Proc Natl Acad Sci U S A*.
413 2016;113(48):13839-13844. doi:10.1073/pnas.1612838113
- 414 21. Centers for Disease Control and Prevention. 2009 Pandemic Influenza A (H1N1)
415 Virus Infections --- Chicago, Illinois, April--July 2009. *Morb Mortal Wkly Rep*.
416 2009;58(33). Accessed May 14, 2020.
417 <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5833a1.htm>
- 418 22. U.S. Bureau of Labor Statistics. Labor force characteristics by race and ethnicity,
419 2018. Published October 2019. Accessed May 14, 2020.
420 <https://www.bls.gov/opub/reports/race-and-ethnicity/2018/home.htm>
- 421 23. Heymann J, Raub A, Waisath W, et al. Protecting health during COVID-19 and
422 beyond: A global examination of paid sick leave design in 193 countries. *Glob*
423 *Public Health*. Published online May 12, 2020:1-10.
424 doi:10.1080/17441692.2020.1764076
- 425 24. Kumar S, Grefenstette JJ, Galloway D, Albert SM, Burke DS. Policies to Reduce
426 Influenza in the Workplace: Impact Assessments Using an Agent-Based Model. *Am*
427 *J Public Health*. 2013;103(8):1406-1411. doi:10.2105/AJPH.2013.301269

- 428 25. Miller ES, Grobman WA, Sakowicz A, Rosati J, Peaceman AM. Clinical
429 Implications of Universal Severe Acute Respiratory Syndrome Coronavirus 2
430 (SARS-CoV-2) Testing in Pregnancy. *Obstet Gynecol.* 2020; Publish Ahead of Print.
431 doi:10.1097/AOG.0000000000003983
- 432 26. Lokken EM, Walker CL, Delaney S, et al. Clinical Characteristics of 46 Pregnant
433 Women with a SARS-CoV-2 Infection in Washington State. *Am J Obstet Gynecol.*
434 Published online May 2020:S0002937820305585. doi:10.1016/j.ajog.2020.05.031
- 435 27. Kelly JC, Dombrowski M, O'neil-Callahan M, Kernberg AS, Frolova AI, Stout MJ.
436 False-Negative COVID-19 Testing: Considerations in Obstetrical Care. *Am J Obstet*
437 *Gynecol MFM.* Published online April 28, 2020:100130.
438 doi:10.1016/j.ajogmf.2020.100130
- 439 28. Long C, Xu H, Shen Q, et al. Diagnosis of the Coronavirus disease (COVID-19):
440 rRT-PCR or CT? *Eur J Radiol.* 2020;126:108961. doi:10.1016/j.ejrad.2020.108961
- 441 29. Li Y, Yao L, Li J, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for
442 hospitalized patients clinically diagnosed with COVID-19. *J Med Virol.* Published
443 online March 26, 2020. doi:10.1002/jmv.25786
- 444 30. Office of Mayor Lori E. Lightfoot. Mayor Lightfoot and the Racial Equity Rapid
445 Response Team Announce Latest Efforts to Address Racial and Health Disparities
446 Among Minority Communities. Published online April 20, 2020. Accessed May 14,
447 2020.

448 https://www.chicago.gov/content/city/en/depts/mayor/press_room/press_releases/20
449 [20/april/RERRTUpdate.html](https://www.chicago.gov/content/city/en/depts/mayor/press_room/press_releases/20/20/april/RERRTUpdate.html)

450 31. Onwuzurike C, Meadows AR, Nour NM. Examining Inequities Associated With
451 Changes in Obstetric and Gynecologic Care Delivery During the Coronavirus
452 Disease 2019 (COVID-19) Pandemic. *Obstet Gynecol*. Published online April 30,
453 2020. doi:10.1097/AOG.0000000000003933

454

455

456

Journal Pre-proof

457 **Table 1: Maternal Characteristics Stratified by SARS-CoV2 Infection Status**

Maternal Characteristic	SARS-CoV2 Status		p-value
	SARS-CoV2 negative n=1317	SARS-CoV2 positive n=101	
Maternal age (y)	33.7 (30.9-36.3)	30.6 (26.2-33.3)	<0.001
Public insurance (n=1408)	218 (16.7%)	62 (62.0%)	<0.001
Race (n=1417)			<0.001
Asian	104 (7.9%)	3 (3.0%)	
Black or African American	141 (10.7%)	28 (28.0%)	
White	772 (58.6%)	23 (23.0%)	
Other/unknown	300 (22.8%)	46 (46.0%)	
Latina ethnicity (n=1341)	244 (19.7%)	53 (53.5%)	<0.001
Married	1027 (78.0%)	40 (39.6%)	<0.001
BMI at delivery (kg/m ²) (n=1307)	29.8 (26.9-33.3)	32.3 (28.9-34.6)	0.002
Obesity (n=1307)	603 (48.0%)	35 (70.0%)	0.002
Tobacco use (n=1413)			
Never	1181 (89.8%)	89 (90.8%)	0.50
Past	119 (9.1%)	7 (7.1%)	
Current	15 (1.1%)	2 (2.0%)	
Any maternal chronic disease (n=1412)	452 (34.3%)	42 (44.2%)	0.051
Pre-existing diabetes	20 (1.5%)	1 (1.0%)	1.00
Hypertension	56 (4.3%)	7 (6.9%)	0.21
Pulmonary disease	179 (13.6%)	22 (21.8%)	0.023
Gestational diabetes (n=1314)	87 (6.9%)	6 (12.8%)	0.12
Nulliparous (n=1415)	677 (51.5%)	30 (30.0%)	<0.001
Any living children (n=1415)	622 (47.3%)	70 (70.0%)	<0.001
Number of living children	0 (0-1)	1 (0-1)	<0.001

458 BMI=body mass index

459 Data presented as median (interquartile range) or n (%)

460

461 **Table 2: Multivariable Analyses for the Outcome of SARS-CoV2 Infection Status**

Maternal Characteristic	Odds Ratio	95% CI	Adjusted Odds Ratio*	95% CI
Maternal age (y)	0.89	0.84-0.94	0.94	0.88-1.01
Public insurance	8.15	5.31-12.53	4.38	2.03-9.48
Race				
Asian	0.96	0.29-3.28	---	---
Black or African American	6.67	3.73-11.91	---	---
White	ref	ref	---	---
Other/unknown	5.15	3.07-8.64	---	---
Latina ethnicity	4.71	3.10-7.17	---	---
Married	0.18	0.12-0.28	---	---
Obesity	2.53	1.36-4.68	1.65	0.82-3.31
Pulmonary disease	1.77	1.08-2.91	1.58	0.78-3.23
Any living children	2.60	1.67-4.04	2.33	1.13-4.78

462 *Model includes maternal age, insurance, obesity, pulmonary disease, and living children

463 **Table 3: Maternal Characteristics by Symptom Presentation**

Maternal Characteristic	Symptoms Present		p-value
	Asymptomatic n=24	Symptomatic n=77	
Maternal age (y)	31.0 (26.2-33.3)	30.4 (25.9-35.6)	0.84
Public insurance	17 (70.8%)	45 (59.2%)	0.31
Nulliparous	6 (25.0%)	24 (31.6%)	0.54
Any living children	18 (75.0%)	52 (68.4%)	0.54
Number of living children	1 (1-2)	1 (0-1)	0.41
Race			0.15
Asian	0 (0.0)	3 (4.0%)	
Black or African American	11 (45.8%)	17 (22.4%)	
White	5 (20.8%)	18 (23.7%)	
Other/unknown	8 (33.3%)	38 (50.0%)	
Latina ethnicity	10 (41.7%)	43 (57.3%)	0.18
Married	6 (25.0%)	34 (44.2%)	0.09
BMI at delivery (kg/m ²) (n=50)	31.2 (28.6-36.5)	32.7 (28.9-34.5)	0.96
Obesity (n=50)	16 (70.0%)	19 (70.4%)	0.95
Tobacco use (n=98)			0.81
Never	21 (91.3%)	68 (90.7%)	
Past	2 (8.7%)	5 (6.7%)	
Current	0 (0.0%)	2 (2.7%)	
Any maternal chronic disease (n=95)	11 (47.8%)	31 (43.1%)	0.69
Pre-existing diabetes	1 (4.2%)	0 (0.0%)	0.24
Hypertension	0 (0.0%)	7 (9.1%)	0.19
Pulmonary disease	5 (20.8%)	17 (22.1%)	0.90
Gestational diabetes (n=47)	2 (8.7%)	4 (16.7%)	0.67

464 BMI=body mass index

465 Data presented as median (interquartile range) or n (%)

466

467

468

469

470


471 **Figure 1: Prevalence of SARS-CoV2 infection stratified by the number of living**
472 **children**
473


Journal Pre-proof

474 **Figure 2: Timeline of study recruitment**

475

Journal Pre-proof







STATEMENT OF AUTHORSHIP

Each author is required to submit a signed Statement of Authorship upon submission. This applies to all submission types including Editorials, Letters to the Editor, etc.

Date: 6/24/20

Manuscript # (if available):

Manuscript title: Risk Factors for SARS-CoV2 Infection in Pregnant Women

Corresponding author: Allie Sakowicz

Authors may either sign the same form or submit individually

I am an author on this submission, have adhered to all editorial policies for submission as described in the Information for Authors, attest to having met all authorship criteria, and all potential conflicts of interest / financial disclosures appears on the title page of the submission.

Signatures are required - typed signatures are unacceptable.

Typed or CLEARLY Printed Name: **Allie Sakowicz**

Signature:

Typed or CLEARLY Printed Name: **Alexander Ayala**

Signature:

Typed or CLEARLY Printed Name: **Chideraa Ukeje**

Signature: 

Typed or CLEARLY Printed Name: **Celeste Witting**

Signature:

Typed or CLEARLY Printed Name: **William A. Grobman** **Signature:**

Typed or CLEARLY Printed Name: **Emily S. Miller**

Signature:

Typed or CLEARLY Printed Name: **Signature:**

Typed or CLEARLY Printed Name: **Signature:**

Journal Pre-proof

STATEMENT OF AUTHORSHIP

Each author is required to submit a signed Statement of Authorship upon submission. This applies to all submission types including Editorials, Letters to the Editor, etc.

Date: 6/24/20

Manuscript # (if available):

Manuscript title: Risk Factors for SARS-CoV2 Infection in Pregnant Women

Corresponding author: Allie Sakowicz

Authors may either sign the same form or submit individually

I am an author on this submission, have adhered to all editorial policies for submission as described in the Information for Authors, attest to having met all authorship criteria, and all potential conflicts of interest / financial disclosures appears on the title page of the submission.

Signatures are required - typed signatures are unacceptable.

Typed or CLEARLY Printed Name: **Allie Sakowicz**

Signature:

Typed or CLEARLY Printed Name: **Alexander Ayala**

Signature: 

Typed or CLEARLY Printed Name: **Chideraa Ukeje**

Signature:

Typed or CLEARLY Printed Name: **Celeste Witting**

Signature:

Typed or CLEARLY Printed Name: **William A. Grobman** **Signature:**

Typed or CLEARLY Printed Name: **Emily S. Miller**

Signature:

Typed or CLEARLY Printed Name: **Signature:**

Typed or CLEARLY Printed Name: **Signature:**

Journal Pre-proof



STATEMENT OF AUTHORSHIP

Each author is required to submit a signed Statement of Authorship upon submission. This applies to all submission types including Editorials, Letters to the Editor, etc.

Date: 6/24/20

Manuscript # (if available):

Manuscript title: Risk Factors for SARS-CoV2 Infection in Pregnant Women

Corresponding author: Allie Sakowicz

Authors may either sign the same form or submit individually

I am an author on this submission, have adhered to all editorial policies for submission as described in the Information for Authors, attest to having met all authorship criteria, and all potential conflicts of interest / financial disclosures appears on the title page of the submission.

Signatures are required - typed signatures are unacceptable. Typed

or CLEARLY Printed Name: Allie Sakowicz

Signature: [Handwritten Signature]

Typed or CLEARLY Printed Name: Alexander Ayala

Signature:

Typed or CLEARLY Printed Name: Chideraa Ukeje

Signature:

Typed or CLEARLY Printed Name: Celeste Witting

Signature:

Typed or CLEARLY Printed Name: William A. Grobman Signature:

Typed or CLEARLY Printed Name: **Emily S. Miller**

Signature:

Typed or CLEARLY Printed Name: **Signature:**

Typed or CLEARLY Printed Name: **Signature:**

Journal Pre-proof

STATEMENT OF AUTHORSHIP

Each author is required to submit a signed Statement of Authorship upon submission. This applies to all submission types including Editorials, Letters to the Editor, etc.

Date: 6/24/20

Manuscript # (if available):

Manuscript title: Risk Factors for SARS-CoV2 Infection in Pregnant Women

Corresponding author: Allie Sakowicz

Authors may either sign the same form or submit individually

I am an author on this submission, have adhered to all editorial policies for submission as described in the Information for Authors, attest to having met all authorship criteria, and all potential conflicts of interest / financial disclosures appears on the title page of the submission.

Signatures are required - typed signatures are unacceptable.

Typed or CLEARLY Printed Name: **Allie Sakowicz**

Signature:

Typed or CLEARLY Printed Name: **Alexander Ayala**

Signature:

Typed or CLEARLY Printed Name: **Chideraa Ukeje**

Signature:

Typed or CLEARLY Printed Name: **Celeste Witting**

Signature:



Typed or CLEARLY Printed Name: **William A. Grobman**

Signature:

Typed or CLEARLY Printed Name: **Emily S. Miller**

Signature:

Typed or CLEARLY Printed Name: **Signature:**

Typed or CLEARLY Printed Name: **Signature:**

Journal Pre-proof